Renata M. C. Ariens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Renata M. C. Ariens has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Jurriaan J. Mes
Wageningen Food and Biobased Research, Wageningen University & Research, Wageningen, The Netherlands
3 shared publications - Liyou Dong
GemPharmatech Co., Nanjing, China
3 shared publications - Coen Govers
Wageningen Food and Biobased Research, Wageningen University & Research, Wageningen, The Netherlands
2 shared publications - Els Oosterink
Wageningen Food and Biobased Research, Wageningen University & Research, 6708 WG Wageningen, The Netherlands
2 shared publications - Harry J. Wichers
Wageningen Food & Biobased Research, Wageningen University & Research, Wageningen, the Netherlands
2 shared publications - Hiroyuki Hoshiko
HE Center, Suntory MONOZUKURI Expert Ltd., Kyoto 619-0284, Japan
2 shared publications
Latest Publications
- Open Access
- 27 June 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 13, 101488
In vitro protein digestibility and colonic fermentation of mycoprotein-based meat analogues
- 27 June 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 13, 101488
Open AccessIn vitro protein digestibility and colonic fermentation of mycoprotein-based meat analogues
- Open Access
- 16 November 2023
- Published by MDPI AG in Proceedings
- Vol. 91 (1) , 47
Daily Lactose Supplementation in Lactase Non-Persistent Individuals Induces Colonic Adaptation and Reduces Intolerance Symptoms
Background and objectives: Globally, about 70% of the adult population is lactase non-persistent (LNP), lacking the enzyme required for lactose digestion. The main consequence of intolerance is withholding nutrient-rich dairy foods, while the literature shows that many LNPers are able to consume ≤12 g of lactose, comparable to 250 mL of milk, without experiencing gastrointestinal discomfort. Repetitive consumption of lactose may improve intolerance symptoms even further via colonic adaptation. This study aimed to assess the effects of daily consumption of incremental lactose doses on microbiota composition and function, and intolerance symptoms. Methods: Twenty-five healthy adults of Asian origin (age 22–44 yrs, BMI 19–28 kg/m2), carrying the LNP genotype and avoiding lactose in their habitual diet, were included in this 12-week single-blinded intervention trial. Participants consumed lactose twice daily, with doses being gradually increased from 3 to 6 g, to finally 12 g twice daily, each dose being provided for 4 consecutive weeks. Before and after the 12-week intervention, participants underwent a 25 g lactose challenge hydrogen breath test (HBT) and handed in stool samples. Daily gastrointestinal symptoms and acute intolerance symptoms during the HBT were recorded. Results: There was a significant increase in Bifidobacterium after 12 weeks of lactose consumption (p = 0.009), accompanied by a two-fold increase (p < 0.001) in fecal β-galactosidase activity. There was a 1.5-fold decrease (AUC; p = 0.01) in expired hydrogen during the second compared to the baseline HBT. There was a non-significant decrease in total symptom score (p = 0.09) during this second HBT, which was already relatively low during the baseline HBT. Daily consumption of lactose was generally well tolerated, with mild to no gastrointestinal complaints reported during the intervention. Discussion: Repetitive consumption of incremental doses of lactose increases lactose tolerance in LNP individuals via colonic adaptation, most likely through increasing the relative abundance of lactose-fermenting Bifidobacterium. Repetitive lactose consumption is well tolerated and able to reduce expired hydrogen during a 25 g lactose HBT. Here, we show that regular and incremental exposure to lactose in LNP individuals leads to colonic adaptation without any increase in gastrointestinal symptoms. This lifts the necessity to remove dairy foods completely from the diet.
- 16 November 2023
- Published by MDPI AG in Proceedings
- Vol. 91 (1) , 47
Open AccessDaily Lactose Supplementation in Lactase Non-Persistent Individuals Induces Colonic Adaptation and Reduces Intolerance Symptoms
Background and objectives: Globally, about 70% of the adult population is lactase non-persistent (LNP), lacking the enzyme required for lactose digestion. The main consequence of intolerance is withholding nutrient-rich dairy foods, while the literature shows that many LNPers are able to consume ≤12 g of lactose, comparable to 250 mL of milk, without experiencing gastrointestinal discomfort. Repetitive consumption of lactose may improve intolerance symptoms even further via colonic adaptation. This study aimed to assess the effects of daily consumption of incremental lactose doses on microbiota composition and function, and intolerance symptoms. Methods: Twenty-five healthy adults of Asian origin (age 22–44 yrs, BMI 19–28 kg/m2), carrying the LNP genotype and avoiding lactose in their habitual diet, were included in this 12-week single-blinded intervention trial. Participants consumed lactose twice daily, with doses being gradually increased from 3 to 6 g, to finally 12 g twice daily, each dose being provided for 4 consecutive weeks. Before and after the 12-week intervention, participants underwent a 25 g lactose challenge hydrogen breath test (HBT) and handed in stool samples. Daily gastrointestinal symptoms and acute intolerance symptoms during the HBT were recorded. Results: There was a significant increase in Bifidobacterium after 12 weeks of lactose consumption (p = 0.009), accompanied by a two-fold increase (p < 0.001) in fecal β-galactosidase activity. There was a 1.5-fold decrease (AUC; p = 0.01) in expired hydrogen during the second compared to the baseline HBT. There was a non-significant decrease in total symptom score (p = 0.09) during this second HBT, which was already relatively low during the baseline HBT. Daily consumption of lactose was generally well tolerated, with mild to no gastrointestinal complaints reported during the intervention. Discussion: Repetitive consumption of incremental doses of lactose increases lactose tolerance in LNP individuals via colonic adaptation, most likely through increasing the relative abundance of lactose-fermenting Bifidobacterium. Repetitive lactose consumption is well tolerated and able to reduce expired hydrogen during a 25 g lactose HBT. Here, we show that regular and incremental exposure to lactose in LNP individuals leads to colonic adaptation without any increase in gastrointestinal symptoms. This lifts the necessity to remove dairy foods completely from the diet.
- Open Access
- 16 December 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (12) , 877
Exploring the Link between Leaky-Gut-Related Markers and Metabolic Health in a Large Dutch Adult Population
A leaky gut can trigger chronic inflammation and poses a primary risk for metabolic diseases. This study established a relationship between intestinal integrity (leaky gut) and metabolic health in a general population. Leaky-gut markers (LGMs) were studied in a large population of Dutch adults with a broad spectrum of metabolic health. This study enrolled 500 individuals selected within the NQplus cohort study (n = 2048) by stratified randomization, based on waist circumference, fasting glucose, and high-density lipoprotein (HDL) cholesterol to obtain a representative and balanced population in terms of metabolic health parameters, sex (male/female), and age (<54/≥54 years). LGMs—zonulin, lipopolysaccharide-binding protein (LBP), and soluble CD14 (sCD14)—were measured in EDTA plasma or serum. Zonulin was most strongly associated with metabolic health. Zonulin and LBP were most strongly associated with the inflammatory marker C-reactive protein (CRP). The quartile analysis for zonulin and LBP showed that most metabolic health parameters and CRP levels increased from Q1 to Q4, with significant differences between quartiles, except for markers related to glucose homeostasis (glucose and glycated hemoglobin A1c (HbA1c)). Associations between LGMs and metabolic health parameters in this large Dutch adult population indicate that LGMs are valuable markers for identifying people at risk of a leaky gut and subsequent chronic inflammation linked to metabolic disorders.
- 16 December 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (12) , 877
Open AccessExploring the Link between Leaky-Gut-Related Markers and Metabolic Health in a Large Dutch Adult Population
A leaky gut can trigger chronic inflammation and poses a primary risk for metabolic diseases. This study established a relationship between intestinal integrity (leaky gut) and metabolic health in a general population. Leaky-gut markers (LGMs) were studied in a large population of Dutch adults with a broad spectrum of metabolic health. This study enrolled 500 individuals selected within the NQplus cohort study (n = 2048) by stratified randomization, based on waist circumference, fasting glucose, and high-density lipoprotein (HDL) cholesterol to obtain a representative and balanced population in terms of metabolic health parameters, sex (male/female), and age (<54/≥54 years). LGMs—zonulin, lipopolysaccharide-binding protein (LBP), and soluble CD14 (sCD14)—were measured in EDTA plasma or serum. Zonulin was most strongly associated with metabolic health. Zonulin and LBP were most strongly associated with the inflammatory marker C-reactive protein (CRP). The quartile analysis for zonulin and LBP showed that most metabolic health parameters and CRP levels increased from Q1 to Q4, with significant differences between quartiles, except for markers related to glucose homeostasis (glucose and glycated hemoglobin A1c (HbA1c)). Associations between LGMs and metabolic health parameters in this large Dutch adult population indicate that LGMs are valuable markers for identifying people at risk of a leaky gut and subsequent chronic inflammation linked to metabolic disorders.
- Open Access
- 19 November 2021
- Published by MDPI AG in Healthcare
- Vol. 9 (11) , 1583
An Observational Study to Evaluate the Association between Intestinal Permeability, Leaky Gut Related Markers, and Metabolic Health in Healthy Adults
We explored whether metabolic health is linked to intestinal permeability, using a multi-sugar (MS) permeability test, and whether intestinal permeability is correlated with the leaky gut-related markers (LGM) zonulin, LBP, and sCD14. Metabolically healthy (n = 15) and unhealthy subjects (n = 15) were recruited based on waist circumference, fasting glucose, and high-density lipoprotein cholesterol levels. Participants underwent an MS permeability test that assessed site-specific permeabilities of the gastroduodenum and small and large intestines. The test was performed with/without an acetylsalicylic acid challenge to measure and correlate the gut permeability, LGM, and metabolic health. At baseline, metabolic health showed no correlation with gut permeability. Significant correlations were found between the metabolic health parameters and LGM. In the acetylsalicylic acid challenged MS permeability test, low-density lipoprotein cholesterol was correlated with the sucralose/erythritol ratio, reflecting the whole intestinal permeability. Correlations between most metabolic health parameters and LGM during the acetylsalicylic acid challenge were less pronounced than at baseline. In both MS permeability tests, no significant correlations were found between LGM (plasma and serum) and gut permeability. Thus, correlations between LGM and metabolic health might not be linked with paracellular gut permeability. Transcellular translocation and/or lipoprotein-related transportation is a more likely mechanism underlying the association between LGM and metabolic health.
- 19 November 2021
- Published by MDPI AG in Healthcare
- Vol. 9 (11) , 1583
Open AccessAn Observational Study to Evaluate the Association between Intestinal Permeability, Leaky Gut Related Markers, and Metabolic Health in Healthy Adults
We explored whether metabolic health is linked to intestinal permeability, using a multi-sugar (MS) permeability test, and whether intestinal permeability is correlated with the leaky gut-related markers (LGM) zonulin, LBP, and sCD14. Metabolically healthy (n = 15) and unhealthy subjects (n = 15) were recruited based on waist circumference, fasting glucose, and high-density lipoprotein cholesterol levels. Participants underwent an MS permeability test that assessed site-specific permeabilities of the gastroduodenum and small and large intestines. The test was performed with/without an acetylsalicylic acid challenge to measure and correlate the gut permeability, LGM, and metabolic health. At baseline, metabolic health showed no correlation with gut permeability. Significant correlations were found between the metabolic health parameters and LGM. In the acetylsalicylic acid challenged MS permeability test, low-density lipoprotein cholesterol was correlated with the sucralose/erythritol ratio, reflecting the whole intestinal permeability. Correlations between most metabolic health parameters and LGM during the acetylsalicylic acid challenge were less pronounced than at baseline. In both MS permeability tests, no significant correlations were found between LGM (plasma and serum) and gut permeability. Thus, correlations between LGM and metabolic health might not be linked with paracellular gut permeability. Transcellular translocation and/or lipoprotein-related transportation is a more likely mechanism underlying the association between LGM and metabolic health.
- Open Access
- 9 July 2021
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 12 (19) , 9248-9260
Clostridioides difficile toxin A-mediated Caco-2 cell barrier damage was attenuated by insect-derived fractions and corresponded to increased gene transcription of cell junctional and proliferation proteins
Protein-enriched insect fractions mitigated Clostridium difficile toxin A-mediated Caco-2 barrier damage by increasing gene transcription of cell junctional and proliferation proteins.
- 9 July 2021
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 12 (19) , 9248-9260
Open AccessClostridioides difficile toxin A-mediated Caco-2 cell barrier damage was attenuated by insect-derived fractions and corresponded to increased gene transcription of cell junctional and proliferation proteins
Protein-enriched insect fractions mitigated Clostridium difficile toxin A-mediated Caco-2 barrier damage by increasing gene transcription of cell junctional and proliferation proteins.
- Open Access
- 16 October 2020
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 64 (23) , e2000324
In Vitro Studies Toward the Use of Chitin as Nutraceutical: Impact on the Intestinal Epithelium, Macrophages, and Microbiota
Scope: Chitin, the most abundant polysaccharide found in nature after cellulose, is known for its ability to support wound healing and to lower plasma‐oxidized low‐density lipoprotein (LDL) levels. Studies have also revealed immunomodulatory potential but contradicting results are often impossible to coalesce through usage of chitin of different or unknown physicochemical consistency. In addition, only a limited set of cellular models have been used to test the bioactivity of chitin.Methods and Results: Chitin is investigated with well‐defined physicochemical consistency for its immunomodulatory potency using THP‐1 macrophages, impact on intestinal epithelial barrier using Caco‐2 cells, and fermentation by fecal‐derived microbiota. Results show that chitin with a degree of acetylation (DA) of ≈83%, regardless of size, does not affect the intestinal epithelial barrier integrity. Large‐sized chitin significantly increases acetic acid production by gut microbiota without altering the composition. Exposure of small‐sized chitin to THP‐1 macrophages lead to significantly increased secretion of IL‐1β, IL‐8, IL‐10, and CXCL10 in a multi‐receptor and clathrin‐mediated endocytosis dependent manner.Conclusions: These findings indicate that small‐sized chitin does not harm the intestinal barrier nor affects SCFA secretion and microbiota composition, but does impact immune activity which could be beneficial to subjects in need of immune support or activation.
- 16 October 2020
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 64 (23) , e2000324
Open AccessIn Vitro Studies Toward the Use of Chitin as Nutraceutical: Impact on the Intestinal Epithelium, Macrophages, and Microbiota
Scope: Chitin, the most abundant polysaccharide found in nature after cellulose, is known for its ability to support wound healing and to lower plasma‐oxidized low‐density lipoprotein (LDL) levels. Studies have also revealed immunomodulatory potential but contradicting results are often impossible to coalesce through usage of chitin of different or unknown physicochemical consistency. In addition, only a limited set of cellular models have been used to test the bioactivity of chitin.Methods and Results: Chitin is investigated with well‐defined physicochemical consistency for its immunomodulatory potency using THP‐1 macrophages, impact on intestinal epithelial barrier using Caco‐2 cells, and fermentation by fecal‐derived microbiota. Results show that chitin with a degree of acetylation (DA) of ≈83%, regardless of size, does not affect the intestinal epithelial barrier integrity. Large‐sized chitin significantly increases acetic acid production by gut microbiota without altering the composition. Exposure of small‐sized chitin to THP‐1 macrophages lead to significantly increased secretion of IL‐1β, IL‐8, IL‐10, and CXCL10 in a multi‐receptor and clathrin‐mediated endocytosis dependent manner.Conclusions: These findings indicate that small‐sized chitin does not harm the intestinal barrier nor affects SCFA secretion and microbiota composition, but does impact immune activity which could be beneficial to subjects in need of immune support or activation.
- 21 November 2017
- Published by Wiley in Flavour and Fragrance Journal
- Vol. 33 (2) , 173-183
A novel functional screening assay to monitor sweet taste receptor activation in vitro
The human sweet taste receptor is a heterodimer comprised of the class C G protein‐coupled receptor (GPCR) subunits TAS1R2 and TAS1R3. A wide collection of sweet tasting compounds and modulators of sweet taste interact with this receptor. Although TAS1R2/TAS1R3‐mediated signaling is well‐studied, the molecular basis for its desensitization remains unclear while such knowledge would signify a profound step forward in understanding the mechanism behind sweet taste perception and taste modulation. In this work, the possible involvement of β‐arrestin in downstream signaling was investigated. A stable clonal Human Embryonic Kidney (HEK)‐derived cell line containing the PathHunter™ GPCR technology was developed, in which β‐arrestin‐mediated endosomal receptor internalization can be monitored by ligand‐induced enzyme complementation of β‐galactosidase (β‐gal). Stimulatory responses and antibody‐specific receptor detection indicated that the TAS1R2/TAS1R3 receptor is endogenously expressed in this clonal cell line. Natural sugars (including fructose, glucose, sucrose, maltose, maltitol and mannitol) and artificial sweeteners (acesulfame‐K and sucralose) stimulated enzyme complementation activity in a concentration dependent manner. Besides, we observed that the assay detected modification of sugar induced cell responses by sweetness enhancers. These results combined implicate that TAS1R2/TAS1R3 receptor desensitization by internalization is most likely mediated by β‐arrestin‐induced endocytosis. This assay approach, making use of naturally expressed TAS1R2/TAS1R3 receptors and required co‐factors, further allows effective screening for and development of novel high potency non‐caloric sweeteners, sweet taste modulators or optimal blends with enhanced sweet taste.
- 21 November 2017
- Published by Wiley in Flavour and Fragrance Journal
- Vol. 33 (2) , 173-183
A novel functional screening assay to monitor sweet taste receptor activation in vitro
The human sweet taste receptor is a heterodimer comprised of the class C G protein‐coupled receptor (GPCR) subunits TAS1R2 and TAS1R3. A wide collection of sweet tasting compounds and modulators of sweet taste interact with this receptor. Although TAS1R2/TAS1R3‐mediated signaling is well‐studied, the molecular basis for its desensitization remains unclear while such knowledge would signify a profound step forward in understanding the mechanism behind sweet taste perception and taste modulation. In this work, the possible involvement of β‐arrestin in downstream signaling was investigated. A stable clonal Human Embryonic Kidney (HEK)‐derived cell line containing the PathHunter™ GPCR technology was developed, in which β‐arrestin‐mediated endosomal receptor internalization can be monitored by ligand‐induced enzyme complementation of β‐galactosidase (β‐gal). Stimulatory responses and antibody‐specific receptor detection indicated that the TAS1R2/TAS1R3 receptor is endogenously expressed in this clonal cell line. Natural sugars (including fructose, glucose, sucrose, maltose, maltitol and mannitol) and artificial sweeteners (acesulfame‐K and sucralose) stimulated enzyme complementation activity in a concentration dependent manner. Besides, we observed that the assay detected modification of sugar induced cell responses by sweetness enhancers. These results combined implicate that TAS1R2/TAS1R3 receptor desensitization by internalization is most likely mediated by β‐arrestin‐induced endocytosis. This assay approach, making use of naturally expressed TAS1R2/TAS1R3 receptors and required co‐factors, further allows effective screening for and development of novel high potency non‐caloric sweeteners, sweet taste modulators or optimal blends with enhanced sweet taste.